Clinical trials in Ukraine
2,736 studies list at least one site in Ukraine. 189 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the studies in Ukraine recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Most studied here
Who runs them
AstraZeneca (141) · Hoffmann-La Roche (111) · Pfizer (109) · Janssen Research & Development, LLC (100) · GlaxoSmithKline (93) · Sanofi (92) · Merck Sharp & Dohme LLC (88) · Boehringer Ingelheim (86)
What changed recently
From the registry's own updates since Oct 11, 2026.
Started recruiting2
First site in Ukraine8
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)Nov 6, 2026NCT07829783
- RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveNov 5, 2026NCT07413939
- Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine TumorsOct 28, 2026NCT07080242
- A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)Oct 28, 2026NCT07647510
- A Study Evaluating TRIV-573 in Atopic DermatitisOct 28, 2026NCT07782333
Show 3 moreShow fewer
- Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Oct 22, 2026NCT07162883
- A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisOct 21, 2026NCT07299019
- A Study of MB-001 in Moderately to Severely Active Ulcerative ColitisOct 20, 2026NCT07374471
Results posted3
- A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung CancerNov 9, 2026NCT04294810
- A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical StudyOct 28, 2026NCT02875548
- Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)Oct 15, 2026NCT04701983
Stopped1
Newly registered4
- From Blast Injury to Multicompartment Dysfunction:Nov 2, 2026NCT07911085
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular RiskOct 28, 2026NCT07900633
- Purse-String Versus Linear Closure After Ileostomy ReversalOct 23, 2026NCT07892404
- Prospective Study on Antimicrobial RESIstance in Chronic Pulmonary DiseasEOct 14, 2026NCT07874139
Studies
Recruiting first, then most recently updated. Showing 50 of 2,736 — search for more.
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)RecruitingNCT03486873Phase 3
- A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)RecruitingNCT06430801Phase 3
- A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)RecruitingNCT06345729Phase 3
- A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe AsthmaRecruitingNCT06023589Phase 3
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)RecruitingNCT06841354Phase 3
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingNCT06966700Phase 3
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)RecruitingNCT06951711Phase 3
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)RecruitingNCT06717347Phase 3
- A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)RecruitingNCT07190248Phase 3
- KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)RecruitingNCT07252739Phase 2
- A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)RecruitingNCT07554339Phase 3
- A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisRecruitingNCT07067463Phase 3
- MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)RecruitingNCT07431827Phase 3
- Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBDEnrolling by invitationNCT07652294Phase 2
- Clinical and Molecular Studies in Families With Inherited Eye DiseaseRecruitingNCT02771236
- Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema AttacksRecruitingNCT06361537Phase 3
- A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)RecruitingNCT07161258Phase 2
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureRecruitingNCT06742723Phase 3
- A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)RecruitingNCT06667700Phase 3
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingNCT05862285Phase 3
- Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With MelanomaRecruitingNCT07476326Phase 1
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)RecruitingNCT07829783Phase 3
- RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveRecruitingNCT07413939Phase 2/3
- A Rollover Study for Continued Study Treatment and Ongoing Safety MonitoringEnrolling by invitationNCT06788509Phase 1
- A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06452277Phase 3
- A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)RecruitingNCT06997497Phase 3
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)RecruitingNCT07241390Phase 3
- LY4268989 in Adults With Moderately to Severely Active Ulcerative ColitisRecruitingNCT07415044Phase 2
- A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)RecruitingNCT07222332Phase 3
- A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisRecruitingNCT07299019Phase 3
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular RiskNot yet recruitingNCT07900633Phase 3
- A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionRecruitingNCT05179876Phase 3
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)RecruitingNCT05139017Phase 2/3
- FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLCRecruitingNCT06303505Phase 1/2
- A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or LamotrigineRecruitingNCT07140913Phase 3
- A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)RecruitingNCT07359846Phase 3
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseaseRecruitingNCT07011745Phase 3
- From Blast Injury to Multicompartment Dysfunction:Not yet recruitingNCT07911085
- Study of XmAb942 in Healthy Participants and Participants With Ulcerative ColitisRecruitingNCT06619990Phase 1/2
- A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)RecruitingNCT07647510Phase 3
- A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusRecruitingNCT07662109Phase 3
- Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine TumorsRecruitingNCT07080242Phase 1
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)RecruitingNCT04165070Phase 1/2
- KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)RecruitingNCT04165798
- Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] MelanomaRecruitingNCT07221734Phase 3
- A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)RecruitingNCT07503873Phase 2
- Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0Enrolling by invitationNCT06823115
- An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab TreatmentRecruitingNCT06675955Phase 3
- Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE ParticipantsRecruitingNCT07201558Phase 1
- A Study Evaluating TRIV-573 in Atopic DermatitisRecruitingNCT07782333Phase 2